Meeting Objectives:
-
- Identify unmet needs for patients with metastatic esophageal SCC and recent trends in using PD-L1 in this treatment space.
- Analyze the latest updates in therapy guidelines and emerging treatment data from clinical trials related to PD-L1 therapy in metastatic esophageal SCC, in order to make informed, patient-specific recommendations through interactive review of complex patient cases.
- Discuss the integral role of pharmacists in the management of metastatic esophageal SCC with PD-L1 therapy, including optimizing patient selection, education, and monitoring.
Share This Event